Resection of primary tumor in stage 4S neuroblastoma: a second study by the Italian Neuroblastoma Group.
Neuroblastoma
Primary tumor resection
Stage 4S
Surgery
Journal
Pediatric surgery international
ISSN: 1437-9813
Titre abrégé: Pediatr Surg Int
Pays: Germany
ID NLM: 8609169
Informations de publication
Date de publication:
Jan 2021
Jan 2021
Historique:
accepted:
11
10
2020
pubmed:
31
10
2020
medline:
22
6
2021
entrez:
30
10
2020
Statut:
ppublish
Résumé
To clarify the role of primary tumor resection in stage 4S neuroblastoma. We investigated a cohort of 172 infants diagnosed with stage 4S neuroblastoma between 1994 and 2013. Of 160 evaluable patients, 62 underwent upfront resection of the primary tumor and 98 did not. Five-year progression-free and overall survival were significantly better in those who had undergone upfront surgery (83.6% vs 64.2% and 96.8% vs 85.7%, respectively). One post-operative death and four non-fatal complications occurred in the resection group. Three patients who had not undergone resection died of chemotherapy-related toxicity. Thirteen patients underwent late surgery to remove a residual tumor, without complications: all but one alive. Outcomes were better in patients diagnosed from 2000 onwards. Infants diagnosed with stage 4S neuroblastoma who underwent upfront tumor resection had a better outcome. However, this result cannot be definitely attributed to surgery, since these patients were selected on the basis of their favorable presenting features. Although the question of whether to operate or not at disease onset is still unsolved, this study confirms the importance of obtaining enough adequate tumor tissue to enable histological and biological studies to properly address treatment, to achieve the best possible outcome.
Identifiants
pubmed: 33123764
doi: 10.1007/s00383-020-04766-1
pii: 10.1007/s00383-020-04766-1
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
37-47Références
D’Angio GJ, Evans AE, Koop C (1971) Special pattern of widespread neuroblastoma with a favorable prognosis. Lancet 1:1046–1049. https://doi.org/10.1016/s0140-6736(71)91606-0
doi: 10.1016/s0140-6736(71)91606-0
pubmed: 4102970
Brodeur GM, Pritchard J, Berthold F et al (1993) Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol 11:1466–1477. https://doi.org/10.1200/JCO.1993.11.8.1466
doi: 10.1200/JCO.1993.11.8.1466
pubmed: 8336186
Brodeur GM (2018) Spontaneous regression of neuroblastoma. Cell Tissue Res. 372:277–286. https://doi.org/10.1007/s00441-017-2761-2
doi: 10.1007/s00441-017-2761-2
pubmed: 29305654
pmcid: 5920563
Evans AE, Chatten J, D’Angio GJ, Gerson JM, Robinson J, Schnaufer L (1980) A review of 17 IV-S neuroblastoma patients at the Children’s Hospital of Philadelphia. Cancer 45:833–839. https://doi.org/10.1002/1097-0142(19800301)45:5%3c833::aid-cncr2820450502%3e3.0.co;2-u
doi: 10.1002/1097-0142(19800301)45:5<833::aid-cncr2820450502>3.0.co;2-u
pubmed: 7260834
Stokes SH, Thomas PR, Perez CA, Vietti TJ (1984) Stage IV-S neuroblastoma: results with definitive therapy. Cancer 53:2083–2086. https://doi.org/10.1002/1097-0142(19840515)53:10%3c2083::aid-cncr2820531014%3e3.0.co;2-s
doi: 10.1002/1097-0142(19840515)53:10<2083::aid-cncr2820531014>3.0.co;2-s
pubmed: 6704896
De Bernardi B, Pianca C, Boni L, Brisigotti M, Carli M, Bagnulo S, Corciulo P, Mancini A, De Laurentis C, Di Tullio MT et al (1992) Disseminated neuroblastoma (stage IV and IV-S) in the first year of life. Cancer 70:1625–1633. https://doi.org/10.1002/1097-0142(19920915)70:6%3c1625::aid-cncr2820700631%3e3.0.co;2-6
doi: 10.1002/1097-0142(19920915)70:6<1625::aid-cncr2820700631>3.0.co;2-6
pubmed: 1516016
Blatt J, Deutsch M, Wollman MR (1987) Results of therapy in stage IV-s neuroblastoma with massive hepatomegaly. Int J Radiat Oncol Biol Phys 13:1467–1471. https://doi.org/10.1016/0360-3016(87)90312-9
doi: 10.1016/0360-3016(87)90312-9
pubmed: 3624025
Katzenstein HM, Bowman LC, Brodeur GM, Thorner PS, Joshi VV, Smith EI, Look AT, Rowe ST, Nash MB, Holbrook T, Alvarado C, Rao PV, Castleberry RP, Cohn SL (1998) Prognostic significance of age, MYCN oncogene amplification, tumor cell ploidy, and histology in 110 infants with stage D(S) neuroblastoma: the Pediatric Oncology Group experience. J Clin Oncol 6:2007–2017. https://doi.org/10.1200/JCO.1998.16.6.2007
doi: 10.1200/JCO.1998.16.6.2007
Nickerson HJ, Matthay KK, Seeger RC, Brodeur GM, Shimada H, Perez C, Atkinson JB, Selch M, Gerbing RB, Stram DO, Lukens J (2000) Favorable biology and outcome of stage IV-S neuroblastoma with supportive care or minimal therapy: a Children’s Cancer Group study. J Clin Oncol 18:477–486. https://doi.org/10.1200/JCO.2000.18.3.477
doi: 10.1200/JCO.2000.18.3.477
pubmed: 10653863
Schleiermacher G, Rubie H, Hartmann O, Bergeron C, Chastagner P, Mechinaud F, Michon J (2003) Neuroblastoma Study Group of the French Society of Paediatric Oncology Treatment of stage 4S neuroblastoma—report of 10 years’ experience of the French Society of Paediatric Oncology (SFOP). Br J Cancer 89:470–476. https://doi.org/10.1038/sj.bjc.6601154
doi: 10.1038/sj.bjc.6601154
pubmed: 12888814
pmcid: 2394373
Taggart DR, London WB, Schmidt ML, DuBois SG, Monclair TF, Nakagawara A, De Bernardi B, Ambros PF, Pearson AD, Cohn SL, Matthay KK (2011) Prognostic value of the stage 4S metastatic pattern and tumor biology in patients with metastatic neuroblastoma diagnosed between birth and 18 months of age. J Clin Oncol 29:4358–4364. https://doi.org/10.1200/JCO.2011.35.9570
doi: 10.1200/JCO.2011.35.9570
pubmed: 21969516
pmcid: 3221520
De Bernardi B, Di Cataldo A, Garaventa A, Massirio P, Viscardi E, Podda MG, Castellano A, D’Angelo P, Tirtei E, Melchionda F, Vetrella S, De Leonardis F, D’Ippolito C, Tondo A, Nonnis A, Erminio G, Gigliotti AR, Mazzocco K, Haupt R (2019) Stage 4s neuroblastoma: features, management and outcome of 268 cases from the Italian Neuroblastoma Registry. Ital J Pediatr 45:8–23. https://doi.org/10.1186/s13052-018-0599-1
doi: 10.1186/s13052-018-0599-1
pubmed: 30634996
pmcid: 6329141
Martinez DA, King DR, Ginn-Pease ME, Haase GM, Wiener ES (1992) Resection of the primary tumor is appropriate for children with stage IV-S neuroblastoma: an analysis of 37 patients. J Pediatr Surg 27:1016–1020. https://doi.org/10.1016/0022-3468(92)90549-m
doi: 10.1016/0022-3468(92)90549-m
pubmed: 1403526
Guglielmi M, De Bernardi B, Rizzo A, Federici S, Boglino C, Siracusa F, Leggio A, Cozzi F, Cecchetto G, Musi L, Bardini T, Fagnani AM, Bartoli GC, Pampaloni A, Rogers D, Conte M, Milanaccio C, Bruzzi P (1996) Resection of primary tumor at diagnosis in stage IV-S neuroblastoma: does it affect the clinical course? J Clin Oncol 14:1537–1544. https://doi.org/10.1200/JCO.1996.14.5.1537
doi: 10.1200/JCO.1996.14.5.1537
pubmed: 8622069
Berthold F, Harms D, Lampert F, Niethammer D, Zieschang J (1990) Risk factors in neuroblastoma of infants. Contrib Oncol 41:101–117. https://doi.org/10.1159/000419225
doi: 10.1159/000419225
Twist CJ, Naranjo A, Schmidt ML, Tenney SC, Cohn SL, Meany HJ, Mattei P, Adkins ES, Shimada H, London WB, Park JR, Matthay KK, Maris JM (2019) Defining risk factors for chemotherapeutic intervention in infants with stage 4S neuroblastoma: a report from Children’s Oncology Group Study ANBL0531. J Clin Oncol 37:115–124. https://doi.org/10.1200/JCO.18.00419
doi: 10.1200/JCO.18.00419
pubmed: 30444686
Haupt R, Garaventa A, Gambini C, Parodi S, Cangemi G, Casale F, Viscardi E, Bianchi M, Prete A, Jenkner A, Luksch R, Di Cataldo A, Favre C, D’Angelo P, Zanazzo GA, Arcamone G, Izzi GC, Gigliotti AR, Pastore G, De Bernardi B (2010) lmproved survival of children with neuroblastoma between 1979 and 2005: a report of the Italian Neuroblastoma Registry. J Clin Oncol 28:2331–2338. https://doi.org/10.1200/JCO.2009.24.8351
doi: 10.1200/JCO.2009.24.8351
pubmed: 20351331
Hsu LL, Evans AE, D’Angio GJ (1996) Hepatomegaly in neuroblastoma stage 4s: criteria for treatment of the vulnerable neonate. Med Pediatr Oncol 27:521–528. https://doi.org/10.1002/(SICI)1096-911X(199612)27:6%3c521::AID-MPO3%3e3.0.CO;2-N
doi: 10.1002/(SICI)1096-911X(199612)27:6<521::AID-MPO3>3.0.CO;2-N
pubmed: 8888811
Shimada H, Ambros IM, Dehner LP, Hata J, Joshi VV, Roald B, Stram DO, Gerbing RB, Lukens JN, Matthay KK, Castleberry RP (1999) The International neuroblastoma pathology classification (the Shimada system). Cancer 86:364–372. https://doi.org/10.1002/(SICI)1097-0142(19990715)86:2%3c364::AID-CNCR21%3e3.0.CO;2-7
doi: 10.1002/(SICI)1097-0142(19990715)86:2<364::AID-CNCR21>3.0.CO;2-7
pubmed: 10421273
Scaruffi P, Parodi S, Mazzocco K, Defferrari R, Fontana V, Bonassi S, Tonini GP (2004) Detection of MYCN amplification and chromosome 1p36 loss in neuroblastoma by cDNA microarray comparative genomic hybridization. Mol Diagn 8:93–100. https://doi.org/10.1007/BF03260051
doi: 10.1007/BF03260051
pubmed: 15527323
Cecchetto G, Mosseri V, De Bernardi B, Helardot P, Monclair T, Costa E, Horcher E, Neuenschwander S, Tomà P, Rizzo A, Michon J, Holmes K (2005) Surgical risk factors in primary surgery for localized neuroblastoma: the LNESG1 Study of the European International Society of Pediatric Oncology Neuroblastoma Group. J Clin Oncol 23:8483–8489. https://doi.org/10.1200/JCO.2005.02.4661
doi: 10.1200/JCO.2005.02.4661
pubmed: 16293878
Monclair T, Brodeur GM, Ambros PF, Brisse HJ, Cecchetto G, Holmes K, Kaneko M, London WB, Matthay KK, Nuchtern JG, von Schweinitz D, Simon T, Cohn SL, Pearson AD, INRG Task Force (2009) The International Neuroblastoma Risk Group (INRG) staging system: an INRG Task Force report. J Clin Oncol 27:298–303. https://doi.org/10.1200/JCO.2008.16.6876
doi: 10.1200/JCO.2008.16.6876
pubmed: 19047290
pmcid: 2650389
De Bernardi B, Gerrard M, Boni L, Rubie H, Cañete A, Di Cataldo A, Castel V, Forjaz de Lacerda A, Ladenstein R, Ruud E, Brichard B, Couturier J, Ellershaw C, Munzer C, Bruzzi P, Michon J, Pearson AD (2009) Excellent outcome with reduced treatment for infants with disseminated neuroblastoma without MYCN amplification. J Clin Oncol 27:1034–1040. https://doi.org/10.1200/JCO.2008.17.5877
doi: 10.1200/JCO.2008.17.5877
pubmed: 19171711
Canete A, Gerrard M, Rubie H, Castel V, Di Cataldo A, Munzer C, Ladenstein R, Brichard B, Bermúdez JD, Couturier J, de Bernardi B, Pearson AJ, Michon J (2009) Poor survival for infants with MYCN-amplified metastatic neuroblastoma despite intensified treatment: the International Society of Paediatric Oncology European Neuroblastoma Experience. J Clin Oncol 27:1014–1019. https://doi.org/10.1200/JCO.2007.14.5839
doi: 10.1200/JCO.2007.14.5839
pubmed: 19171715
Hosmer DW, Lemeshow S (1999) Applied survival analysis—regression modeling of time to event data. Wiley, New York
European Low and Intermediate Neuroblastoma: a SIOPEN Study version 3.0, 30 May 2011 https://www.docvadis.fr/files/all/JI3RO1LMf9PWrlqN9k7X7w/neuroblastome_low_intermediate_risk_lines_protocol_version_4_2_2_janvier_2013.pdf .
Keene DJ, Minford J, Craigie RJ, Humphrey G, Bruce J (2001) Laparostomy closure in stage 4S neuroblastoma. J Pediatr Surg 46:1–4. https://doi.org/10.1016/j.jpedsurg.2010.08.064
doi: 10.1016/j.jpedsurg.2010.08.064
Weintraub M, Bloom AI, Gross E, Revel-Vilk S, Shahroor S, Koplewitz BZ, Freeman AI (2004) Successful treatment of progressive stage 4s hepatic neuroblastoma in a neonate with intra-arterial chemoembolization. Pediatr Blood Cancer 43:148–151. https://doi.org/10.1002/pbc.20080
doi: 10.1002/pbc.20080
pubmed: 15236281
Holsten T, Schuster T, Grabhorn E, Hero B, Frühwald MC (2017) Liver transplantation as a potentially life-saving measure in neuroblastoma stage 4S. Pediatr Hematol Oncol 34:17–23. https://doi.org/10.1080/08880018.2016.1266535
doi: 10.1080/08880018.2016.1266535
pubmed: 28085536
Schleiermacher G, Michon J, Ribeiro A, Pierron G, Mosseri V, Rubie H, Munzer C, Bénard J, Auger N, Combaret V, Janoueix-Lerosey I, Pearson A, Tweddle DA, Bown N, Gerrard M, Wheeler K, Noguera R, Villamon E, Cañete A, Castel V, Marques B, de Lacerda A, Tonini GP, Mazzocco K, Defferrari R, De Bernardi B, Di Cataldo A, van Roy N, Brichard B, Ladenstein R, Ambros I, Ambros P, Beiske K, Delattre O, Couturier J (2011) Segmental chromosomal alterations lead to a higher risk of relapse in infants with MYCN-non-amplified localized unresectable/disseminated neuroblastoma (a SIOPEN collaborative study). Br J Cancer 107:1418–1422. https://doi.org/10.1038/bjc.2011.472
doi: 10.1038/bjc.2011.472
Raitio A, Rice MJ, Mullassery D, Losty PD (2020) Stage 4S neuroblastoma: what are the outcomes? A systematic review of published studies. Eur J Pediatr Surg. https://doi.org/10.1055/s-0040-1716836.10.1055/s-0040-1716836 (published online ahead of print, 2020 Sep 15)
doi: 10.1055/s-0040-1716836.10.1055/s-0040-1716836
pubmed: 32932540